Drugs / PF-08046054
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05208762 | Oct 2022 → Jan 2028 expected | endometrial cancer, esophageal squamous cell carcinoma, gastric cancer, head and neck squamous cell carcinoma +4 | Pfizer | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07144280 | Sep 2025 → Mar 2028 expected | non-small cell lung carcinoma | Pfizer | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-04-21 | Pfizer | Results Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026 pfizer.com ↗
Reduction in circulating tumor DNA (ctDNA) significantly correlates with radiographic response and tumor PD-L1 expression in a phase 1 study of PDL1V (PF-08046054) in patients with non-small cell lung cancer (NSCLC) |
| 2024-09-11 | Pfizer | Results Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024 pfizer.com ↗
Pfizer will also present early clinical-stage research for a number of priority pipeline areas, including encouraging Phase 1 results of the potential first-in-class antibody-drug conjugate (ADC) candidate SGN-PDL1V (PF-08046054) in NSCLC and head and neck squamous cell carcinoma (HNSCC); |
| 2024-02-29 | Pfizer | Results Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth pfizer.com ↗
During the meeting, Pfizer also shared new or updated clinical data from various pipeline programs, including atirmociclib, ELREXFIO, felmetatug vedotin (B7H4 ADC), mevrometostat (EZH2i), PD-L1 ADC (PF-08046054), and sigvatutag vedotin. |
All press releases naming this drug 3 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-08046054 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07144280 ↗ |
| Modality | Other / unclassified | “Antibody Drug Conjugate” NCT07144280 ↗ |
| Route | Intravenous | “Given into the vein (IV; intravenously)” NCT05208762 ↗ |